Karyopharm Therapeutics prices upsized IPO at $16, the high end of the range

By
A A A

Karyopharm Therapeutics, an early-stage biotech developing treatments for cancer by targeting nuclear transport, raised $109 million by offering 6.8 million (up from 5.7 million) shares at $16, the high end of the range of $14 to $16. Karyopharm Therapeutics plans to list on the NASDAQ under the symbol KPTI. Karyopharm Therapeutics initially filed confidentially on 9/5/2013. BofA Merrill Lynch and Leerink Swann acted as joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: KPTI

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Cheap Ways to Sleep Better
Cheap Ways to Sleep Better          

Stocks

Referenced

100%

Most Active by Volume

105,679,298
  • $16.13 ▼ 0.19%
43,130,824
  • $101.32 ▲ 0.74%
24,108,376
  • $59.80 ▲ 7.34%
22,524,427
  • $26.15 ▼ 1.06%
22,194,114
  • $24.65 ▼ 0.96%
21,835,360
  • $99.05 ▲ 0.15%
20,872,575
  • $34.94 ▼ 0.60%
20,561,803
    $74.57 unch
As of 8/22/2014, 04:02 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com